Mallinckrodt has started patient recruitment in a Phase IIa clinical trial of MNK-6106 (L-ornithine phenylacetate) for the treatment of hepatic (liver) cirrhosis and hepatic encephalopathy (HE).
Akari Therapeutics has reported positive results from an ongoing Phase II clinical trial assessing nomacopan for the treatment of an autoimmune inflammatory skin disease called bullous pemphigoid (BP).
AstraZeneca has reported positive results from the Phase III Flaura trial evaluating Tagrisso (osimertinib) in previously untreated patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC).
Coordination Pharmaceuticals (CPI) has dosed the first patient in a Phase I study of nanoscale coordination polymer (NCP) CPI-200 in patients with advanced tumours.
Arrowhead Pharmaceuticals has initiated a potentially pivotal Phase II/III clinical trial of ARO-AAT, its second generation subcutaneously administered RNA interference (RNAi) therapeutic.
Sometimes, You Have to Move to Go Forward PhenoSwitch Biosource is proud to announce that it will be operating from a new space in the beautiful Sherbrooke, Quebec, Canada.
Immunoassay Technology Gyrolab users regard this system as a must-have technology for accelerating biopharmaceutical development and production.
Getting Acquainted with the Theory of XRF This white paper provides a general introduction to X-ray Fluorescence (CRF) spectrometry and XRF analysis. It explains how a spectrometer works and how XRF analysis is achieved.
Thanks for reading. If you enjoyed this newsletter, please share with colleagues, friends and anybody else, get them to sign up and join the conversation. You can contact us at marketing@verdict.co.uk.
Up-to-date international news and features on the Healthcare industry
You are receiving this email because you are either a valued subscriber to Verdict Drug Development Technology or have signed up via a partner website. Your email address has not been, and will not be, given to third parties.
